While many people view spring as a time of renewal and hope, the greatest number of suicides in the United States occur each year in April and May, notes the American College of Emergency Physicians.
It's not clear why suicide rates spike in the spring, said ACEP President Dr. Linda L. Lawrence. But "we do know that suicide is the 11th leading cause of death for all ages in the United States, with one suicide occurring every 16 minutes or about 11 suicides per 100,000 people," she said in a prepared statement.
"Moreover, suicide is the second leading cause of death among 25- to 34-year-olds and the third leading cause of death among 15- to 24-year-olds. Men take their own lives nearly four times more often than women, with men ages 75 and older having the highest rate of suicide, although over a lifetime, women attempt suicide two to three times as often as men," Lawrence said.
READ MORE @ US NEWS & WORLD REPORT
Showing posts with label prevention. Show all posts
Showing posts with label prevention. Show all posts
Monday, March 24, 2008
Monday, August 13, 2007
Efexor* XL (venlafaxine) May Help Adult Patients Prevent Recurrent Episodes of Depression for Up to Two Years
Clinical trial data showing that Efexor* XL (venlafaxine) helped patients prevent the recurrence of depression for up to two years1a, was presented at the British Association for Psychopharmacology summer meeting in Harrogate. It is the first time that a modern antidepressant has demonstrated prevention of recurrence, versus placebo, over a two year period.2 These findings reinforce guidance from the National Institute for Health and Clinical Excellence (NICE), that anti-depressants should be continued for two years in patients who have had 2 or more episodes. 3
Results from the Prevention of Recurrent Episodes of Depression with VENlafaxine XR for Two Years (PREVENT)1b study demonstrated that 70% of patients continued to respond to treatment with venlafaxine at doses 225mg/day and less over 2 years1c, and were therefore significantly more likely to remain recurrence-free than patients taking placebo.
READ MORE @ HEALTHCARE REPUBLIC
Results from the Prevention of Recurrent Episodes of Depression with VENlafaxine XR for Two Years (PREVENT)1b study demonstrated that 70% of patients continued to respond to treatment with venlafaxine at doses 225mg/day and less over 2 years1c, and were therefore significantly more likely to remain recurrence-free than patients taking placebo.
READ MORE @ HEALTHCARE REPUBLIC
Subscribe to:
Posts (Atom)
